Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dawn Baker

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2014
Tumor stromal phenotypes define VEGF sensitivity--responseNeil R Smith, Dawn Baker, Matthew Farren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapyNeil R Smith, Dawn Baker, Matthew Farren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2010
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancersNeil R Smith, Dawn Baker, Neil H James, et al.
Cancer Research|February 29, 2012
AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase familyPaul R Gavine, Lorraine Mooney, Elaine Kilgour, et al.
Molecular Cancer Therapeutics|August 24, 2016
Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547Oona Delpuech, Claire Rooney, Lorraine Mooney, et al.
Human Gene Therapy|November 23, 2006
Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adultsMark L Brantly, L Terry Spencer, Margaret Humphries, et al.
Plos One|February 25, 2016
Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous AmpliconClaire Rooney, Catherine Geh, Victoria Williams, et al.
International Journal of Oncology|May 4, 2011
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerSandra R Brave, Rajesh Odedra, Neil H James, et al.
Molecular Cancer Therapeutics|June 9, 2012
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivoDavid W Jenkins, Sarah Ross, Margaret Veldman-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancerKevin Sharpe, Grant D Stewart, Alan Mackay, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2014
Tumor stromal phenotypes define VEGF sensitivity--responseNeil R Smith, Dawn Baker, Matthew Farren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapyNeil R Smith, Dawn Baker, Matthew Farren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2010
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancersNeil R Smith, Dawn Baker, Neil H James, et al.
Cancer Research|February 29, 2012
AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase familyPaul R Gavine, Lorraine Mooney, Elaine Kilgour, et al.
Molecular Cancer Therapeutics|August 24, 2016
Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547Oona Delpuech, Claire Rooney, Lorraine Mooney, et al.
Human Gene Therapy|November 23, 2006
Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adultsMark L Brantly, L Terry Spencer, Margaret Humphries, et al.
Plos One|February 25, 2016
Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous AmpliconClaire Rooney, Catherine Geh, Victoria Williams, et al.
International Journal of Oncology|May 4, 2011
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerSandra R Brave, Rajesh Odedra, Neil H James, et al.
Molecular Cancer Therapeutics|June 9, 2012
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivoDavid W Jenkins, Sarah Ross, Margaret Veldman-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancerKevin Sharpe, Grant D Stewart, Alan Mackay, et al.
Pageof 3